Dual‐hormone artificial pancreas: benefits and limitations compared with single‐hormone systems

Dual‐hormone artificial pancreas: benefits and limitations compared with single‐hormone systems What's new?We review the literature comparing the relative efficacy and utility of single‐ and dual‐hormone artificial pancreas systems.The pharmacokinetic profile of glucagon, with rapid onset and short duration of action, confers the major benefit of the dual‐hormone artificial pancreas.The dual‐hormone artificial pancreas is superior to single‐hormone systems in reducing hypoglycaemia overall and during exercise in short‐term studies, whereas there is no strong evidence of added benefit for preventing nocturnal or post‐exercise hypoglycaemia.The relative benefit of each system over the long term for improving HbA1c, preventing severe hypoglycaemia, and affecting quality of life remains unknown.IntroductionThe benefits of tight glycaemic control for reducing microvascular complications and all‐cause mortality in Type 1 diabetes must be balanced with the increased risk of hypoglycaemia and the elevated burden of diabetes self‐management that accompanies intensive glucose control. Moreover, fear of hypoglycaemia often leads to permissive hyperglycaemia, which is reflected in suboptimal HbA1c levels in people with Type 1 diabetes .With advances in technology, including continuous glucose monitoring and continuous subcutaneous insulin infusion (CSII) pumps (‘insulin pumps’), the burden of self‐monitoring capillary blood glucose and of multiple daily subcutaneous insulin injections is reduced. Recent evidence points to increased utilization of these emerging technologies, particularly among the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diabetic Medicine Wiley

Dual‐hormone artificial pancreas: benefits and limitations compared with single‐hormone systems

Loading next page...
 
/lp/wiley/dual-hormone-artificial-pancreas-benefits-and-limitations-compared-45dNzzbjNa
Publisher
Wiley
Copyright
Diabetic Medicine © 2018 Diabetes UK
ISSN
0742-3071
eISSN
1464-5491
D.O.I.
10.1111/dme.13581
Publisher site
See Article on Publisher Site

Abstract

What's new?We review the literature comparing the relative efficacy and utility of single‐ and dual‐hormone artificial pancreas systems.The pharmacokinetic profile of glucagon, with rapid onset and short duration of action, confers the major benefit of the dual‐hormone artificial pancreas.The dual‐hormone artificial pancreas is superior to single‐hormone systems in reducing hypoglycaemia overall and during exercise in short‐term studies, whereas there is no strong evidence of added benefit for preventing nocturnal or post‐exercise hypoglycaemia.The relative benefit of each system over the long term for improving HbA1c, preventing severe hypoglycaemia, and affecting quality of life remains unknown.IntroductionThe benefits of tight glycaemic control for reducing microvascular complications and all‐cause mortality in Type 1 diabetes must be balanced with the increased risk of hypoglycaemia and the elevated burden of diabetes self‐management that accompanies intensive glucose control. Moreover, fear of hypoglycaemia often leads to permissive hyperglycaemia, which is reflected in suboptimal HbA1c levels in people with Type 1 diabetes .With advances in technology, including continuous glucose monitoring and continuous subcutaneous insulin infusion (CSII) pumps (‘insulin pumps’), the burden of self‐monitoring capillary blood glucose and of multiple daily subcutaneous insulin injections is reduced. Recent evidence points to increased utilization of these emerging technologies, particularly among the

Journal

Diabetic MedicineWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off